https://news.medxy.ai/zh/standardizing-rct-evidence/Medxy AIzh2026-08-07T21:30:44-07:00厘清基于登记数据库的随机对照试验：以标准化与分类学推动临床证据进阶 https://news.medxy.ai/ja/registry-randomized-trial/Medxy AIja2026-08-07T21:30:19-07:00レジストリベースランダム化比較試験を読み解く：標準化と分類体系による臨床エビデンスの前進 https://news.medxy.ai/vi/randomized-trials/Medxy AIvi2026-08-07T21:30:00-07:00Giải mã các thử nghiệm đối chứng ngẫu nhiên dựa trên sổ đăng ký: Thúc đẩy bằng chứng lâm sàng thông qua chuẩn hóa và hệ thống phân loại https://news.medxy.ai/decoding-registry-based-randomised-controlled-trials-advancing-clinical-evidence-through-standardisation-and-taxonomy/Medxy AIen2026-08-07T21:28:44-07:00Decoding Registry-Based Randomised Controlled Trials: Advancing Clinical Evidence Through Standardisation and Taxonomy https://news.medxy.ai/zh/type-2-diabetes-treatment/Medxy AIzh2026-08-07T21:15:12-07:00TriMaster试验：2型糖尿病精准治疗策略谁更优？临床特征模型胜出 https://news.medxy.ai/ja/trimaster-diabetes-treatment/Medxy AIja2026-08-07T21:14:49-07:00TriMaster試験で検証：2型糖尿病治療における精密アプローチの比較 https://news.medxy.ai/optimizing-type-2-diabetes-treatment-comparing-precision-approaches-in-the-trimaster-trial/Medxy AIen2026-08-07T21:13:04-07:00Optimizing Type 2 Diabetes Treatment: Comparing Precision Approaches in the TriMaster Trial https://news.medxy.ai/zh/cardiac-resynchronization-therapy-in-nonischemic-cardiomyopathy/Medxy AIzh2026-08-07T12:38:38-07:00非缺血性心肌病中CRT是否需要联合除颤器？——基于DECIDE-CRT及相关研究的证据综述与临床启示 https://news.medxy.ai/ja/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy/Medxy AIja2026-08-07T12:38:15-07:00非虚血性心筋症におけるCRTは除細動器併用が必要か：DECIDE-CRTと関連研究から読み解くエビデンスと臨床的含意 https://news.medxy.ai/vi/cardiac-resynchronization-therapy-with-or-without-defibrillator/Medxy AIvi2026-08-07T12:37:45-07:00Liệu pháp tái đồng bộ tim có hoặc không kèm máy khử rung ở bệnh cơ tim không do thiếu máu cục bộ: Tổng hợp bằng chứng và hàm ý lâm sàng từ DECIDE-CRT và các nghiên cứu liên quan https://news.medxy.ai/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy-2/Medxy AIen2026-08-07T12:36:09-07:00Cardiac Resynchronization Therapy With or Without Defibrillator in Nonischemic Cardiomyopathy: Evidence Synthesis and Clinical Implications from DECIDE-CRT and Related Studies https://news.medxy.ai/zh/u-shaped-between-left-ventricular-and-mortality-in-heart-failure/Medxy AIzh2026-08-07T12:32:53-07:00左心室大小与心力衰竭死亡风险：U型关系的临床启示 https://news.medxy.ai/ja/u-shaped-between-left-ventricular-size-and-mortality-in-heart-failure/Medxy AIja2026-08-07T12:32:35-07:00心不全における左室サイズと死亡率のU字型関係を読み解く https://news.medxy.ai/vi/u-shaped-relationship-between-left-ventricular-size-and-mortality-in-heart-failure/Medxy AIvi2026-08-07T12:32:16-07:00Giải mã mối liên quan hình chữ U giữa kích thước thất trái và tử vong ở bệnh nhân suy tim https://news.medxy.ai/decoding-the-u-shaped-relationship-between-left-ventricular-size-and-mortality-in-heart-failure-patients/Medxy AIen2026-08-07T12:31:15-07:00Decoding the U-Shaped Relationship Between Left Ventricular Size and Mortality in Heart Failure Patients https://news.medxy.ai/zh/combined-transcatheter-mitral-and-tricuspid-edge-to-edge-repair-in-patients-with-moderate-mitral-regurgitation-and-severe-tricuspid-regurgitation/Medxy AIzh2026-08-07T12:07:55-07:00联合经导管二尖瓣与三尖瓣缘对缘修复在中度二尖瓣反流合并重度三尖瓣反流患者中的临床影响 https://news.medxy.ai/transcatheter-mitral-and-tricuspid-edge-to-edge-repair-in-patients-with-moderate-mitral-regurgitation/Medxy AIen2026-08-07T12:06:02-07:00Impact of Combined Transcatheter Mitral and Tricuspid Edge-to-Edge Repair in Patients with Moderate Mitral Regurgitation and Severe Tricuspid Regurgitation https://news.medxy.ai/zh/7-year-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIzh2026-08-07T12:04:58-07:00TAVR 与 SAVR 在低风险主动脉瓣狭窄患者中的 7 年健康结局：PARTNER 3 试验解读 https://news.medxy.ai/ja/7-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIja2026-08-07T12:04:38-07:00低リスク大動脈弁狭窄症におけるTAVRとSAVRの7年転帰：PARTNER 3試験から得られた知見 https://news.medxy.ai/vi/seven-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIvi2026-08-07T12:04:18-07:00Sau 7 năm, TAVR và SAVR mang lại kết cục sức khỏe ra sao ở bệnh nhân hẹp động mạch chủ nguy cơ thấp? Dữ liệu từ thử nghiệm PARTNER 3 https://news.medxy.ai/seven-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients-insights-from-the-partner-3-trial/Medxy AIen2026-08-07T12:03:14-07:00Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 Trial https://news.medxy.ai/zh/lv-hypertrabeculation-in-dilated-cardiomyopathy/Medxy AIzh2026-08-07T12:01:02-07:00扩张型心肌病中的左心室过度肌小梁化：预后提示与临床意义 https://news.medxy.ai/ja/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy/Medxy AIja2026-08-07T12:00:44-07:00拡張型心筋症における左室過剰肉柱形成：予後の見通しと臨床的意義 https://news.medxy.ai/vi/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy-prognostic/Medxy AIvi2026-08-07T12:00:24-07:00Tăng bè thất trái trong bệnh cơ tim giãn: ý nghĩa tiên lượng và hàm ý lâm sàng https://news.medxy.ai/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy-prognostic-insights-and-clinical-implications/Medxy AIen2026-08-07T11:59:04-07:00Left Ventricular Hypertrabeculation in Dilated Cardiomyopathy: Prognostic Insights and Clinical Implications https://news.medxy.ai/zh/electronic-patient-reported-outcome-with-alert-based-interventions-in-metastatic-breast-cancer-2/Medxy AIzh2026-08-07T11:55:09-07:00转移性乳腺癌的电子患者报告结局监测：警报触发干预的证据与临床启示 https://news.medxy.ai/ja/electronic-patient-reported-outcome-with-alert-based-interventions-in-metastatic-breast-cancer/Medxy AIja2026-08-07T11:54:46-07:00転移性乳がんにおける電子患者報告アウトカムモニタリングとアラート介入：エビデンスと臨床的意義の整理 https://news.medxy.ai/vi/electronic-patient-reported-outcome-monitoring-with-alert-based-interventions-in-metastatic-breast-cancer/Medxy AIvi2026-08-07T11:54:21-07:00Theo dõi kết cục do người bệnh tự báo cáo bằng điện tử trong ung thư vú di căn: bằng chứng và ý nghĩa lâm sàng của can thiệp dựa trên cảnh báo https://news.medxy.ai/electronic-patient-reported-outcome-monitoring-with-alert-based-interventions-in-metastatic-breast-cancer-a-review-of-evidence-and-clinical-implications/Medxy AIen2026-08-07T11:53:17-07:00Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Review of Evidence and Clinical Implications https://news.medxy.ai/zh/enfortumab-vedotin-induced-cutaneous-toxicity-and-survival-in-urothelial-carcinoma/Medxy AIzh2026-08-07T11:49:11-07:00恩福妥珠单抗维多汀相关皮肤毒性：晚期尿路上皮癌生存获益的潜在标志 https://news.medxy.ai/ja/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-survival-in-urothelial-carcinoma/Medxy AIja2026-08-07T11:48:48-07:00エンホルツマブ ベドチンによる皮膚毒性は予後改善のサインか：進行尿路上皮癌における生存との関連 https://news.medxy.ai/vi/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-survival-in-advanced-urothelial-carcinoma/Medxy AIvi2026-08-07T11:48:07-07:00Độc tính da do Enfortumab Vedotin: Dấu ấn gợi ý cải thiện sống còn trong ung thư biểu mô niệu mô tiến triển https://news.medxy.ai/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-improved-survival-in-advanced-urothelial-carcinoma/Medxy AIen2026-08-07T11:47:03-07:00Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma https://news.medxy.ai/zh/antifungal-therapies-for-tinea-capitis/Medxy AIzh2026-08-07T11:46:23-07:00头癣抗真菌治疗效果如何？中国多中心研究给出新线索 https://news.medxy.ai/ja/efficacy-of-antifungal-therapies-for-tinea-capitis/Medxy AIja2026-08-07T11:46:05-07:00頭部白癬に対する抗真菌治療の有効性：中国の多施設研究から見えたこと https://news.medxy.ai/vi/efficacy-of-antifungal-therapies-in-tinea-capitis/Medxy AIvi2026-08-07T11:45:45-07:00Điều trị nấm da đầu: hiệu quả của các thuốc kháng nấm qua nghiên cứu đa trung tâm tại Trung Quốc https://news.medxy.ai/efficacy-of-antifungal-therapies-in-tinea-capitis-insights-from-a-multicenter-study-in-china/Medxy AIen2026-08-07T11:44:32-07:00Efficacy of Antifungal Therapies in Tinea Capitis: Insights from a Multicenter Study in China https://news.medxy.ai/zh/migraine-and-sinus-headaches-in-patients-with-primary-rhinoplasty/Medxy AIzh2026-08-07T11:42:13-07:00初次鼻整形患者中偏头痛与鼻窦性头痛的发生率：临床综述 https://news.medxy.ai/ja/migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty/Medxy AIja2026-08-07T11:41:52-07:00一次鼻形成術における片頭痛・副鼻腔頭痛の頻度：臨床レビュー https://news.medxy.ai/vi/frequency-of-migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty/Medxy AIvi2026-08-07T11:41:28-07:00Đau nửa đầu và đau đầu do xoang ở bệnh nhân phẫu thuật tạo hình mũi nguyên phát: tổng quan lâm sàng https://news.medxy.ai/frequency-of-migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty-a-clinical-review/Medxy AIen2026-08-07T11:40:24-07:00Frequency of Migraine and Sinus Headaches in Patients Undergoing Primary Rhinoplasty: A Clinical Review https://news.medxy.ai/zh/%e6%8f%90%e5%8d%87%e4%b9%b3%e6%88%bf%e7%9a%ae%e7%93%a3%e5%ad%98%e6%b4%bb%e8%af%84%e4%bc%b0%ef%bc%9a%e6%bf%80%e5%85%89%e6%95%a3%e6%96%91%e5%af%b9%e6%af%94%e6%88%90%e5%83%8f%e4%b8%8e%e5%90%b2%e5%93%9a/Medxy AIzh2026-08-07T11:38:52-07:00提升乳房皮瓣存活评估：激光散斑对比成像与吲哚菁绿荧光谁更优 https://news.medxy.ai/ja/%e4%b9%b3%e6%88%bf%e3%83%95%e3%83%a9%e3%83%83%e3%83%97%e7%94%9f%e5%ad%98%e6%80%a7%e8%a9%95%e4%be%a1%e3%81%ae%e6%96%b0%e5%b1%95%e9%96%8b%ef%bc%9a%e3%83%ac%e3%83%bc%e3%82%b6%e3%83%bc%e3%83%bb%e3%82%b9/Medxy AIja2026-08-07T11:38:21-07:00乳房フラップ生存性評価の新展開：レーザー・スペックル・コントラスト・イメージングとインドシアニングリーン蛍光法の比較 https://news.medxy.ai/vi/nang-cao-danh-gia-kha-nang-song-cua-vat-vu-laser-speckle-contrast-imaging-so-voi-huynh-quang-indocyanine-green/Medxy AIvi2026-08-07T11:38:01-07:00Nâng cao đánh giá khả năng sống của vạt vú: Laser Speckle Contrast Imaging so với huỳnh quang Indocyanine Green https://news.medxy.ai/advancing-breast-flap-viability-assessment-laser-speckle-contrast-imaging-versus-indocyanine-green-fluorescence/Medxy AIen2026-08-07T11:37:15-07:00Advancing Breast Flap Viability Assessment: Laser Speckle Contrast Imaging Versus Indocyanine Green Fluorescence https://news.medxy.ai/zh/higher-education-students-in-england-who-died-by-suspected-suicide-a-national-retrospective-case-series-study/Medxy AIzh2026-08-07T11:35:04-07:00英格兰高等教育学生疑似自杀死亡特征：一项全国性回顾性病例系列研究 https://news.medxy.ai/vi/characteristics-of-higher-education-students-in-england-who-died-by-suspected-suicide/Medxy AIvi2026-08-07T11:34:15-07:00Đặc điểm của sinh viên giáo dục đại học ở Anh tử vong do nghi ngờ tự sát: nghiên cứu chuỗi ca hồi cứu toàn quốc https://news.medxy.ai/characteristics-of-higher-education-students-in-england-who-died-by-suspected-suicide-a-national-retrospective-case-series-study/Medxy AIen2026-08-07T11:32:39-07:00Characteristics of Higher-Education Students in England Who Died by Suspected Suicide: A National Retrospective Case Series Study https://news.medxy.ai/zh/h3-1-nucleosomes-for-renal-replacement-therapy-and-mortality-in-sepsis/Medxy AIzh2026-08-07T11:24:41-07:00H3.1 核小体作为脓毒症肾脏替代治疗与死亡风险预测生物标志物：来自 SISPCT 试验的分析 https://news.medxy.ai/ja/h3-1-nucleosomes-as-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis/Medxy AIja2026-08-07T11:24:06-07:00敗血症の予後予測を担うH3.1ヌクレオソーム：腎代替療法と死亡率を見据えたSISPCT試験解析 https://news.medxy.ai/vi/h3-1-nucleosomes-as-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis-insights-from-the-sispct-trial/Medxy AIvi2026-08-07T11:23:28-07:00Nucleosome H3.1 như dấu ấn sinh học tiên lượng trong điều trị thay thế thận và tử vong ở nhiễm khuẩn huyết: phân tích từ thử nghiệm SISPCT https://news.medxy.ai/h3-1-nucleosomes-as-predictive-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis-insights-from-the-sispct-trial/Medxy AIen2026-08-07T11:21:32-07:00H3.1 Nucleosomes as Predictive Biomarkers for Renal Replacement Therapy and Mortality in Sepsis: Insights from the SISPCT Trial https://news.medxy.ai/zh/enhance-trust-empathy-and-comfort-in-serious-illness-communication-4/Medxy AIzh2026-08-07T11:06:57-07:00医生的情绪表达与自我披露：如何在严重疾病沟通中增强信任、同理心与舒适感 https://news.medxy.ai/ja/enhance-trust-empathy-and-comfort-in-serious-illness-communication-3/Medxy AIja2026-08-07T11:06:31-07:00重篤な疾患の対話をより良くするには：医師の感情表出と自己開示が信頼・思いやりに与える好影響 https://news.medxy.ai/vi/enhance-trust-empathy-and-comfort-in-serious-illness-communication-2/Medxy AIvi2026-08-07T11:06:12-07:00Cảm xúc và sự chân thành của bác sĩ trong trao đổi về bệnh nặng: củng cố niềm tin và lòng trắc ẩn https://news.medxy.ai/zh/effectiveness-of-2024-2025-covid19-vaccines-in-adults/Medxy AIzh2026-08-07T11:04:02-07:002024—2025年成人 COVID-19 疫苗有效性估计：近期证据的综合综述 https://news.medxy.ai/ja/effectiveness-of-2024-2025-covid-19-vaccines-in-adults/Medxy AIja2026-08-07T11:03:31-07:00成人における2024～2025年COVID-19ワクチンの有効性推定：最新エビデンスの包括的レビュー https://news.medxy.ai/vi/estimated-effectiveness-of-2024-2025-covid-19-vaccines-in-adults/Medxy AIvi2026-08-07T11:03:08-07:00Hiệu quả của vắc xin COVID-19 2024–2025 ở người lớn: Tổng quan toàn diện về bằng chứng gần đây https://news.medxy.ai/estimated-effectiveness-of-2024-2025-covid-19-vaccines-in-adults-a-comprehensive-review-of-recent-evidence/Medxy AIen2026-08-07T11:00:13-07:00Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults: A Comprehensive Review of Recent Evidence https://news.medxy.ai/ja/acp-2026-position-paper-a-policy-roadmap-to-obesity/Medxy AIja2026-08-07T10:56:17-07:00ACP 2026年声明：肥満予防・治療を「手が届く・受けやすい・スティグマのない」ものにするための政策ロードマップ https://news.medxy.ai/vi/acp-2026-position-paper-a-policy-roadmap-to-obesity-prevention-and-treatment/Medxy AIvi2026-08-07T10:55:37-07:00ACP 2026: Lộ trình chính sách giúp phòng ngừa và điều trị béo phì trở nên dễ tiếp cận, hợp túi tiền và không kỳ thị https://news.medxy.ai/zh/acp-2026-position-paper-a-policy-roadmap-to-make-obesity-prevention-and-treatment/Medxy AIzh2026-08-07T10:54:57-07:00ACP 2026立场文件：让肥胖预防与治疗更可负担、可及并消除污名的政策路线图 https://news.medxy.ai/acp-2026-position-paper-a-policy-roadmap-to-make-obesity-prevention-and-treatment-affordable-accessible-and-stigma-free/Medxy AIen2026-08-07T10:51:17-07:00ACP 2026 Position Paper: A Policy Roadmap to Make Obesity Prevention and Treatment Affordable, Accessible, and Stigma-Free https://news.medxy.ai/zh/advancing-diagnosis-in-myeloproliferative-neoplasms-non-invasive-multiparametric-profiling/Medxy AIzh2026-08-07T10:49:12-07:00破解骨髓增殖性肿瘤诊断难题：ET、前纤维化期与显性骨髓纤维化的非侵入性多参数分型 https://news.medxy.ai/ja/noninvasive-multiparametric-for-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIja2026-08-07T10:48:54-07:00骨髄増殖性腫瘍の診断を前進させる：ET、前線維化期骨髄線維症、顕性骨髄線維症を非侵襲的多項目プロファイリングで読み解く https://news.medxy.ai/vi/non-invasive-multiparametric-for-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIvi2026-08-07T10:48:25-07:00Cải thiện chẩn đoán trong các u tăng sinh tủy: hồ sơ đa thông số không xâm lấn của ET, preMF và PMF xơ hóa rõ https://news.medxy.ai/advancing-diagnosis-in-myeloproliferative-neoplasms-non-invasive-multiparametric-profiling-of-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIen2026-08-07T10:47:13-07:00Advancing Diagnosis in Myeloproliferative Neoplasms: Non-invasive Multiparametric Profiling of ET, Premyelofibrosis, and Overt Myelofibrosis https://news.medxy.ai/zh/swisslegio-score-legionella-in-community-acquired-pneumonia/Medxy AIzh2026-08-07T10:18:26-07:00SwissLEGIO 评分：简化社区获得性肺炎中军团菌检测的实用工具 https://news.medxy.ai/ja/swisslegio-score-legionella-testing-in-community-acquired-pneumonia/Medxy AIja2026-08-07T10:17:53-07:00SwissLEGIOスコア：地域性肺炎におけるレジオネラ検査を効率化する簡便な指標 https://news.medxy.ai/vi/swisslegio-score-streamline-legionella-testing-in-community-acquired-pneumonia/Medxy AIvi2026-08-07T10:17:30-07:00SwissLEGIO: Thang điểm đơn giản hóa giúp tối ưu xét nghiệm Legionella trong viêm phổi mắc phải cộng đồng https://news.medxy.ai/swisslegio-score-a-simplified-tool-to-streamline-legionella-testing-in-community-acquired-pneumonia/Medxy AIen2026-08-07T10:16:23-07:00SwissLEGIO Score: A Simplified Tool to Streamline Legionella Testing in Community-Acquired Pneumonia https://news.medxy.ai/zh/diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-for-acute-appendicitis/Medxy AIzh2026-08-07T09:41:32-07:00急性阑尾炎中 RIPASA 评分与修正 Alvarado 评分谁更准？——来自印度三级中心的比较研究 https://news.medxy.ai/ja/diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-in-acute-appendicitis/Medxy AIja2026-08-07T09:41:14-07:00急性虫垂炎におけるRIPASAスコアと修正Alvaradoスコアの診断精度比較：インド三次医療施設からの知見 https://news.medxy.ai/vi/comparative-diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-in-acute-appendicitis/Medxy AIvi2026-08-07T09:40:54-07:00RIPASA hay Alvarado sửa đổi: thang điểm nào chẩn đoán viêm ruột thừa cấp tốt hơn? https://news.medxy.ai/comparative-diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-in-acute-appendicitis-insights-from-an-indian-tertiary-centre/Medxy AIen2026-08-07T09:39:25-07:00Comparative Diagnostic Accuracy of RIPASA and Modified Alvarado Scores in Acute Appendicitis: Insights from an Indian Tertiary Centre https://news.medxy.ai/zh/the-race-free-mesa-risk-score/Medxy AIzh2026-08-07T09:12:19-07:00重审心血管风险评估中的种族/族裔变量：无种族/族裔 MESA 风险评分 https://news.medxy.ai/ja/assessment-the-race-free-mesa-risk-score/Medxy AIja2026-08-07T09:12:03-07:00心血管リスク評価における人種・民族の再考：人種を用いないMESAリスクスコア https://news.medxy.ai/vi/race-ethnicity-in-cardiovascular-risk-assessment-the-race-free-mesa-risk-score/Medxy AIvi2026-08-07T09:11:45-07:00Xem xét lại vai trò của chủng tộc/sắc tộc trong đánh giá nguy cơ tim mạch: thang điểm MESA không sử dụng chủng tộc/sắc tộc https://news.medxy.ai/rethinking-race-ethnicity-in-cardiovascular-risk-assessment-the-race-free-mesa-risk-score/Medxy AIen2026-08-07T09:10:24-07:00Rethinking Race/Ethnicity in Cardiovascular Risk Assessment: The Race-Free MESA Risk Score https://news.medxy.ai/zh/lace-and-hospital-scores-for-30-day-readmissions/Medxy AIzh2026-08-07T09:02:20-07:00巴基斯坦三级医院中LACE与HOSPITAL评分预测30天再入院的价值评估 https://news.medxy.ai/ja/evaluating-lace-and-hospital-scores-for-predicting-30-day-readmissions/Medxy AIja2026-08-07T09:02:05-07:00パキスタン三次医療機関における30日再入院予測：LACEスコアとHOSPITAL scoreの有用性を検証 https://news.medxy.ai/vi/enhance-trust-empathy-and-comfort-in-serious-illness-communication/Medxy AIvi2026-08-07T09:01:37-07:00Đánh giá điểm LACE và HOSPITAL trong dự báo tái nhập viện 30 ngày tại bệnh viện tuyến cuối ở Pakistan https://news.medxy.ai/evaluating-lace-and-hospital-scores-for-predicting-30-day-readmissions-in-a-pakistani-tertiary-care-setting/Medxy AIen2026-08-07T08:59:03-07:00Evaluating LACE and HOSPITAL Scores for Predicting 30-day Readmissions in a Pakistani Tertiary Care Setting https://news.medxy.ai/zh/bpnt1-mutations-as-cause-of-vitaminb12-dependent-megaloblastic-anemia/Medxy AIzh2026-08-07T08:58:29-07:00BPNT1 突变：维生素 B12 依赖性巨幼细胞性贫血的新病因 https://news.medxy.ai/ja/bpnt1-mutations-as-cause-of-vitamin-b12-dependent-megaloblastic-anemia/Medxy AIja2026-08-07T08:58:13-07:00BPNT1変異が切り開く、ビタミンB12依存性巨赤芽球性貧血の新規病因 https://news.medxy.ai/vi/bpnt1-mutations-as-a-novel-cause-of-vitamin-b12-dependent-megaloblastic-anemia/Medxy AIvi2026-08-07T08:57:55-07:00Đột biến BPNT1: Nguyên nhân di truyền mới của thiếu máu nguyên hồng cầu khổng lồ phụ thuộc vitamin B12 https://news.medxy.ai/unveiling-bpnt1-mutations-as-a-novel-cause-of-vitamin-b12-dependent-megaloblastic-anemia/Medxy AIen2026-08-07T08:56:18-07:00Unveiling BPNT1 Mutations as a Novel Cause of Vitamin B12-Dependent Megaloblastic Anemia https://news.medxy.ai/zh/surface-topographic-assessment-of-forced-pulmonary-maneuvers-spirometry/Medxy AIzh2026-08-07T08:27:54-07:00无标记表面地形学评估用力呼气动作：在健康受试者中与肺量计的一致性及可靠性 https://news.medxy.ai/ja/surface-topographic-assessment-of-forced-pulmonary-maneuvers-reliability-with-spirometry/Medxy AIja2026-08-07T08:27:29-07:00健常者における努力呼出操作の表面トポグラフィ評価：信頼性とスパイロメトリーとの一致性 https://news.medxy.ai/vi/surface-topographic-assessment-of-forced-pulmonary-maneuvers-reliability-and-agreement-with-spirometry/Medxy AIvi2026-08-07T08:27:07-07:00Đánh giá địa hình bề mặt trong các nghiệm pháp thở gắng sức: Độ tin cậy và mức độ phù hợp với hô hấp ký ở người khỏe mạnh https://news.medxy.ai/surface-topographic-assessment-of-forced-pulmonary-maneuvers-reliability-and-agreement-with-spirometry-in-healthy-participants/Medxy AIen2026-08-07T08:24:47-07:00Surface Topographic Assessment of Forced Pulmonary Maneuvers: Reliability and Agreement with Spirometry in Healthy Participants https://news.medxy.ai/zh/interleukin-6-in-acute-lung-injury-covid19/Medxy AIzh2026-08-06T12:56:07-07:00白细胞介素-6：急性肺损伤与COVID-19治疗获益的关键枢纽 https://news.medxy.ai/ja/interleukin-6-in-acute-lung-injury-covid-19/Medxy AIja2026-08-06T12:55:50-07:00急性肺障害とCOVID-19における治療成功を導く中心因子としてのInterleukin-6 https://news.medxy.ai/vi/interleukin-6-in-acute-lung-injury-and-covid-19/Medxy AIvi2026-08-06T12:55:24-07:00IL-6: mắt xích trung tâm quyết định hiệu quả điều trị trong tổn thương phổi cấp và COVID-19 https://news.medxy.ai/interleukin-6-as-a-central-mediator-of-therapeutic-success-in-acute-lung-injury-and-covid-19/Medxy AIen2026-08-06T12:54:35-07:00Interleukin-6 as a Central Mediator of Therapeutic Success in Acute Lung Injury and COVID-19 https://news.medxy.ai/zh/understanding-and-reducing-diagnostic-delays-in-childhood-uveitis/Medxy AIzh2026-08-06T12:00:29-07:00缩短儿童起病葡萄膜炎的诊断延误：识别并减少确诊迟滞 https://news.medxy.ai/ja/reducing-diagnostic-delays-in-childhood-onset-uveitis/Medxy AIja2026-08-06T12:00:12-07:00小児発症ブドウ膜炎の診断遅延をどう減らすか：その要因と対策を読み解く https://news.medxy.ai/vi/understanding-and-reducing-diagnostic-delays-in-childhood-onset-uveitis/Medxy AIvi2026-08-06T11:59:51-07:00Vượt qua khoảng trễ chẩn đoán: hiểu và giảm trì hoãn trong uveitis khởi phát ở trẻ em https://news.medxy.ai/bridging-the-gap-understanding-and-reducing-diagnostic-delays-in-childhood-onset-uveitis/Medxy AIen2026-08-06T11:59:02-07:00Bridging the Gap: Understanding and Reducing Diagnostic Delays in Childhood Onset Uveitis https://news.medxy.ai/zh/global-axial-length-centile-for-myopia-management-in-children-and-adolescents/Medxy AIzh2026-08-06T11:58:23-07:00全球儿童青少年眼轴长度百分位曲线：近视管理的新参考标准 https://news.medxy.ai/ja/global-axial-length-centile-charts-for-myopia-management-in-children-and-adolescents/Medxy AIja2026-08-06T11:58:08-07:00小児・思春期の近視管理に役立つ新指標：世界規模の眼軸長パーセンタイルチャート https://news.medxy.ai/vi/myopia-management-in-children-and-adolescents/Medxy AIvi2026-08-06T11:57:49-07:00Biểu đồ bách phân vị độ dài trục nhãn cầu toàn cầu: Nguồn tham chiếu mới cho quản lý cận thị ở trẻ em và thanh thiếu niên https://news.medxy.ai/global-axial-length-centile-charts-a-new-reference-for-myopia-management-in-children-and-adolescents/Medxy AIen2026-08-06T11:56:59-07:00Global Axial Length Centile Charts: A New Reference for Myopia Management in Children and Adolescents